Antibody-drug conjugates and uses thereof
AssigneeImmunomedics, Inc.
InventorsDavid M. Goldenberg, Serengulam V. Govindan
Life of this patent
Estimating the term…
Loading patent…
AssigneeImmunomedics, Inc.
InventorsDavid M. Goldenberg, Serengulam V. Govindan
Estimating the term…
The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to Trop-2 or CEACAM5 and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Surprisingly, the immunoconjugate is effective to treat cancers that are refractory to or relapsed from irinotecan.
-44. (canceled)
A method of treating head and neck cancer comprising administering to a human patient with head and neck cancer an immunoconjugate sacituzumab govitecan (IMMU-132) wherein the immunoconjugate is administered at a dosage of between 6 mg/kg and 12 mg/kg.
Dependencies are inferred from the claim text.